New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment

Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment

September 20, 2021YaleIn a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.Nikhil Joshi, PhDIn a new study byYale
World medicine November 16,2023
Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment

Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment

September 20, 2021YaleIn a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.Nikhil Joshi, PhDIn a new study byYale
World medicine November 16,2023
Novel Drug Targets Stem Cell Activity in Pancreatic Cancer

Novel Drug Targets Stem Cell Activity in Pancreatic Cancer

March 21, 2019Brittany LovelyNapabucasin, a novel therapy that targets cancer stem cell pathways, is being investigated in a phase III clinical trial that is believed to be the largest study ever cond
World medicine November 16,2023
Novel Drug Targets Stem Cell Activity in Pancreatic Cancer

Novel Drug Targets Stem Cell Activity in Pancreatic Cancer

March 21, 2019Brittany LovelyNapabucasin, a novel therapy that targets cancer stem cell pathways, is being investigated in a phase III clinical trial that is believed to be the largest study ever cond
World medicine November 16,2023
Allogeneic HSCT Retains Role in Relapsed Myeloma

Allogeneic HSCT Retains Role in Relapsed Myeloma

March 15, 2019Brandon ScaleaSergio A. Giralt, MD, discusses recent data with allogeneic hematopoietic stem cell therapy and why this long-standing modality remains an integral part of treatment for pa
World medicine November 16,2023
Allogeneic HSCT Retains Role in Relapsed Myeloma

Allogeneic HSCT Retains Role in Relapsed Myeloma

March 15, 2019Brandon ScaleaSergio A. Giralt, MD, discusses recent data with allogeneic hematopoietic stem cell therapy and why this long-standing modality remains an integral part of treatment for pa
World medicine November 16,2023
Allogeneic HSCT Linked With Favorable Survival Outcomes in Myelofibrosis

Allogeneic HSCT Linked With Favorable Survival Outcomes in Myelofibrosis

August 5, 2021Ryan ScottThough there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative
World medicine November 16,2023
Allogeneic HSCT Linked With Favorable Survival Outcomes in Myelofibrosis

Allogeneic HSCT Linked With Favorable Survival Outcomes in Myelofibrosis

August 5, 2021Ryan ScottThough there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative
World medicine November 16,2023
Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

November 15, 2023Mount SinaiA first-of-its-kind study unveils how diabetes drives multiple myeloma growth and differences in survival outcomes for Black versus white patients with both conditionsSamir
World medicine November 16,2023
Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

November 15, 2023Mount SinaiA first-of-its-kind study unveils how diabetes drives multiple myeloma growth and differences in survival outcomes for Black versus white patients with both conditionsSamir
World medicine November 16,2023
Plinabulin Combo Shows Potential Reduction in Neutropenia Burden in Patients With Myeloma Who Underwent AHCT

Plinabulin Combo Shows Potential Reduction in Neutropenia Burden in Patients With Myeloma Who Underwent AHCT

August 29, 2022Kristi RosaThe combination of plinabulin and pegfilgrastim was well tolerated patients with multiple myeloma who have undergone autologous hematopoietic stem cell transplantation and wh
World medicine November 16,2023
Plinabulin Combo Shows Potential Reduction in Neutropenia Burden in Patients With Myeloma Who Underwent AHCT

Plinabulin Combo Shows Potential Reduction in Neutropenia Burden in Patients With Myeloma Who Underwent AHCT

August 29, 2022Kristi RosaThe combination of plinabulin and pegfilgrastim was well tolerated patients with multiple myeloma who have undergone autologous hematopoietic stem cell transplantation and wh
World medicine November 16,2023
European Commission Approves Adjuvant Pembrolizumab for High-Risk NSCLC

European Commission Approves Adjuvant Pembrolizumab for High-Risk NSCLC

October 16, 2023Caroline SeymourThe European Commission has approved pembrolizumab as adjuvant monotherapy for the treatment of adult patients with non–small cell lung cancer who are at high risk of r
World medicine November 16,2023
European Commission Approves Adjuvant Pembrolizumab for High-Risk NSCLC

European Commission Approves Adjuvant Pembrolizumab for High-Risk NSCLC

October 16, 2023Caroline SeymourThe European Commission has approved pembrolizumab as adjuvant monotherapy for the treatment of adult patients with non–small cell lung cancer who are at high risk of r
World medicine November 16,2023
Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

May 5, 2023Kristi RosaThe phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end
World medicine November 16,2023
Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

May 5, 2023Kristi RosaThe phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end
World medicine November 16,2023
Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL

Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL

May 5, 2022Ashling WahnerThe combination of bendamustine and rituximab plus autologous stem cell transplantation and maintenance rituximab was shown to be an effective first-line treatment with compar
World medicine November 16,2023
Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL

Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL

May 5, 2022Ashling WahnerThe combination of bendamustine and rituximab plus autologous stem cell transplantation and maintenance rituximab was shown to be an effective first-line treatment with compar
World medicine November 16,2023
Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics

Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics

August 26, 2022Jordyn SavaThe triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progr
World medicine November 16,2023
Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics

Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics

August 26, 2022Jordyn SavaThe triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progr
World medicine November 16,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com